NEW YORK – Radiopharm Theranostics on Tuesday said it was cleared by Australian regulators to begin a Phase I trial of its KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or ...

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.